DUBLIN--(BUSINESS WIRE)--The "Autoinjectors Market by Therapy (Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Cardiovascular diseases, Psoriasis, Migraine), Type (Disposable, and Reusable), End Users (Homecare, and Hospitals) - Global Forecast to 2023" report has been added to ResearchAndMarkets.com's offering.
The global autoinjectors market is expected to reach USD 85.31 billion by 2023 from an estimated USD 28.91 billion in 2018, at a CAGR of 24.2% during the forecast period.
Growing prevalence of targeted therapies, rising incidence of anaphylaxis, increasing number of regulatory approvals, and technological advancements in autoinjector devices are expected to drive the growth of the autoinjectors market. However, the preference for alternative routes of drug delivery such as oral diabetic agents and epinephrine nasal sprays is expected to restrain the growth of this market to a certain extent.
Based on therapy, the global autoinjectors market is segmented into rheumatoid arthritis, multiple sclerosis, diabetes, anaphylaxis, and other therapies. The rheumatoid arthritis segment is expected to grow at the highest CAGR during the forecast period. The high growth of the segment can be primarily attributed to the high prevalence of rheumatoid arthritis across the globe.
Based on type, the market is segmented into disposable and reusable autoinjectors. The disposable autoinjectors segment is expected to grow at the highest CAGR during the forecast period. This can be attributed to the benefits these autoinjectors offer, such as portability, ease of use, and a lower possibility of infection.
North America is expected to witness the highest growth from 2018 to 2023. This can be attributed to the rising prevalence of anaphylaxis, autoimmune diseases, and chronic diseases in the US and Canada; favorable reimbursement scenario; and increasing number of awareness programs in the region.
Key Topics Covered: 1 Introduction
2 Research Methodology
3 Executive Summary
4 Premium Insights
5 Market Overview
6 Autoinjectors Market, By Therapy
7 Autoinjectors Market, By Type
8 Autoinjectors Market, By End User
9 Autoinjectors Market, By Region
10 Competitive Landscape
11 Company Profiles
- Abbvie
- Amgen
- Teva
- Biogen
- Eli Lilly
- Mylan
- Merck
- Ypsomed
- AstraZeneca
- J&J
- Becton Dickinson and Company
- Owen Mumford
- Novartis
- Bayer
- Haselmeier
For more information about this report visit https://www.researchandmarkets.com/research/qtm6ml/autoinjectors?w=4
